| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ayla Güven, Tolga Ozgen, Umit Belet, Murat Aydi. Acromegaly symptoms without pituitary adenoma in an adolescent. Journal of pediatric endocrinology & metabolism : JPEM. vol 20. issue 8. 2007-11-09. PMID:17937067. |
the diagnosis of acromegaly requires a glucose-suppressed growth hormone (gh) nadir greater than 1 microg/l associated with clinical symptoms and signs. |
2007-11-09 |
2023-08-12 |
Not clear |
| Mehmet Bastemir, Fulya Akin, Guzin Fidan Yaylal. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly. Neuroendocrinology. vol 86. issue 2. 2007-10-23. PMID:17671378. |
despite combined therapy consisting of surgery, external x-ray, and medical therapy, a significant number of acromegaly patients continue to have uncontrolled growth hormone (gh) secretion and active disease. |
2007-10-23 |
2023-08-12 |
Not clear |
| Mehmet Bastemir, Fulya Akin, Guzin Fidan Yaylal. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly. Neuroendocrinology. vol 86. issue 2. 2007-10-23. PMID:17671378. |
our aim was to investigate whether patients with documented gh-secreting pituitary adenomas leading to acromegaly would respond with attenuation of gh and insulin-like growth factor-1 (igf-1) levels after treatment with a peroxisome proliferator-activated receptor gamma (ppar-gamma) agonist. |
2007-10-23 |
2023-08-12 |
Not clear |
| Demet Ozgil Yetkin, Serife Nur Boysan, Ozay Tiryakioglu, Ayse Serap Yalin, Pinar Kadiogl. Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide. Endocrine journal. vol 54. issue 3. 2007-10-18. PMID:17495423. |
the objective of the present study was to investigate the effects of octreotide long acting release (s-lar) preparation on gh and igf-1 serum concentrations and pituitary tumor size in patients with persistent and difficultly controlled acromegaly even after adjuvant irradiation and/or dopamine agonists. |
2007-10-18 |
2023-08-12 |
Not clear |
| Amar Agha, John P Monso. Modulation of glucocorticoid metabolism by the growth hormone - IGF-1 axis. Clinical endocrinology. vol 66. issue 4. 2007-09-18. PMID:17371460. |
this interaction has clinically significant implications as it may at least partly explain the phenotypes of acromegaly and adult gh deficiency and the effects that treatment of these conditions has on body composition. |
2007-09-18 |
2023-08-12 |
Not clear |
| b' Vicente Climent, Francisco Mar\\xc3\\xadn, Antonio Pic\\xc3\\xb. Pharmacologic therapy in growth hormone disorders and the heart. Current medicinal chemistry. vol 14. issue 13. 2007-09-17. PMID:17584052.' |
acromegaly, entity characterized by gh hypersecretion, is associated with an increased risk of premature death. |
2007-09-17 |
2023-08-12 |
Not clear |
| b' Vicente Climent, Francisco Mar\\xc3\\xadn, Antonio Pic\\xc3\\xb. Pharmacologic therapy in growth hormone disorders and the heart. Current medicinal chemistry. vol 14. issue 13. 2007-09-17. PMID:17584052.' |
the aim of the present review is to provide an update overview describing the role of gh on acromegaly, adult gh deficiency and heart failure, as well as the influence of gh-based therapy on heart structure and function. |
2007-09-17 |
2023-08-12 |
Not clear |
| Sylvia L Asa, Rebecca Digiovanni, Jing Jiang, Megan L Ward, Kimberly Loesch, Shozo Yamada, Toshiaki Sano, Katsuhiko Yoshimoto, Stuart J Frank, Shereen Ezza. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer research. vol 67. issue 15. 2007-09-11. PMID:17671221. |
those that cause growth hormone (gh) excess and acromegaly are subdivided into morphologic variants that have not yet been shown to have pathogenetic significance or predictive value for therapy and outcome. |
2007-09-11 |
2023-08-12 |
human |
| Sylvia L Asa, Rebecca Digiovanni, Jing Jiang, Megan L Ward, Kimberly Loesch, Shozo Yamada, Toshiaki Sano, Katsuhiko Yoshimoto, Stuart J Frank, Shereen Ezza. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer research. vol 67. issue 15. 2007-09-11. PMID:17671221. |
it explains the lack of responsiveness to somatostatin analogue therapy of this tumor type, in contrast to the exquisite sensitivity of tumors that lack aggresomes, and has therapeutic implications for the safety of gh antagonism as a therapeutic modality in acromegaly. |
2007-09-11 |
2023-08-12 |
human |
| Christoph Schmid, Pierre-Alexandre Krayenbuehl, René-Ludwig Bernays, Cornelia Zwimpfer, Friedrich E Maly, Peter Wiesl. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. Clinical chemistry. vol 53. issue 8. 2007-09-04. PMID:17573420. |
growth hormone (gh) receptor isoform in acromegaly: lower concentrations of gh but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the gh receptor gene. |
2007-09-04 |
2023-08-12 |
Not clear |
| Christoph Schmid, Pierre-Alexandre Krayenbuehl, René-Ludwig Bernays, Cornelia Zwimpfer, Friedrich E Maly, Peter Wiesl. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. Clinical chemistry. vol 53. issue 8. 2007-09-04. PMID:17573420. |
the aim of this study was to test whether the relationship between gh and insulin-like growth factor-1 (igf-1) concentrations is influenced by the ghr genotype in patients with acromegaly. |
2007-09-04 |
2023-08-12 |
Not clear |
| Charles A Hurty, Bente Flatlan. Feline acromegaly: a review of the syndrome. Journal of the American Animal Hospital Association. vol 41. issue 5. 2007-08-13. PMID:16141180. |
acromegaly is characterized by chronic excessive growth hormone (gh) secretion by the pituitary gland. |
2007-08-13 |
2023-08-12 |
Not clear |
| Niki Karavitaki, John A H Was. Pegvisomant: a new treatment modality for acromegaly. Hormones (Athens, Greece). vol 3. issue 1. 2007-06-19. PMID:16982575. |
acromegaly, a multisystemic disease resulting from excessive growth hormone (gh) and insulin-like growth factor-i (igf-i) levels in adults, is associated with a two-to-threefold increase in mortality. |
2007-06-19 |
2023-08-12 |
Not clear |
| Giselle Fernandes Taboada, Lívia Lugarinho Correa, Evelyn de Oliveira Machado, Flávia Regina van Haute, Alessandra Ferri Casini, Giovanna Aparecida Balarini, Leonardo Vieira Neto, Lilia Calixto, Cláudia Calixto, Mônica Roberto Gadelh. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 17. issue 1. 2007-06-12. PMID:17314058. |
gh secretion, in acromegaly, is characterized by increased basal levels, as well as by increased frequency and amplitude of pulses. |
2007-06-12 |
2023-08-12 |
Not clear |
| Rune Lindberg-Larsen, Niels Møller, Ole Schmitz, Søren Nielsen, Marianne Andersen, Hans Orskov, Jens O L Jørgense. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 92. issue 5. 2007-06-06. PMID:17341562. |
pegvisomant is a specific gh receptor antagonist that is able to normalize serum igf-i concentrations in most patients with acromegaly. |
2007-06-06 |
2023-08-12 |
Not clear |
| Gaddameedi R Reddy, Mary J Pushpanathan, Richard F Ransom, Lawrence B Holzman, Frank C Brosius, Maria Diakonova, Peter Mathieson, Moin A Saleem, Edward O List, John J Kopchick, Stuart J Frank, Ram K Meno. Identification of the glomerular podocyte as a target for growth hormone action. Endocrinology. vol 148. issue 5. 2007-06-04. PMID:17272398. |
these results provide a novel mechanistic link between gh's actions and glomerular dysfunction in disorders such as acromegaly and diabetic glomerulosclerosis. |
2007-06-04 |
2023-08-12 |
human |
| Martin Bidlingmaier, Christian J Strasburge. What endocrinologists should know about growth hormone measurements. Endocrinology and metabolism clinics of North America. vol 36. issue 1. 2007-05-11. PMID:17336737. |
determination of human growth hormone (gh) concentration in serum plays a key role in the diagnosis of gh deficiency and gh excess (acromegaly). |
2007-05-11 |
2023-08-12 |
human |
| David R Clemmon. Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinology and metabolism clinics of North America. vol 36. issue 1. 2007-05-11. PMID:17336738. |
free igf-i, igf binding protein-3, or acid-labile subunit may provide useful information regarding gh secretion in specific conditions but are not superior to igf-i for making the diagnosis of gh deficiency or acromegaly. |
2007-05-11 |
2023-08-12 |
Not clear |
| A N Paisley, K Hayden, A Ellis, J Anderson, G Wieringa, P J Traine. Pegvisomant interference in GH assays results in underestimation of GH levels. European journal of endocrinology. vol 156. issue 3. 2007-04-30. PMID:17322491. |
pegvisomant use in acromegaly negates the use of gh levels to monitor disease activity. |
2007-04-30 |
2023-08-12 |
Not clear |
| Katherine M Morrison, Martin Bidlingmaier, Simone Stadler, Zida Wu, Lars Skriver, Christian J Strasburge. Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly. European journal of endocrinology. vol 156. issue 3. 2007-04-30. PMID:17322493. |
the usefulness of measuring the gh-dependent acid-labile subunit (als) in the management of gh deficiency (ghd) and acromegaly remains in question and is investigated in this study, comparing several different immunoassays for als. |
2007-04-30 |
2023-08-12 |
Not clear |